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A B S T R A C T
The ability to estimate the age of the donor from recovered biological material at a crime scene can be of
substantial value in forensic investigations. Aging can be complex and is associated with various
molecular modiﬁcations in cells that accumulate over a person’s lifetime including epigenetic patterns.
The aim of this study was to use age-speciﬁc DNA methylation patterns to generate an accurate model for
the prediction of chronological age using data from whole blood. In total, 45 age-associated CpG sites
were selected based on their reported age coefﬁcients in a previous extensive study and investigated
using publicly available methylation data obtained from 1156 whole blood samples (aged 2–90 years)
analysed with Illumina’s genome-wide methylation platforms (27 K/450 K). Applying stepwise
regression for variable selection, 23 of these CpG sites were identiﬁed that could signiﬁcantly contribute
to age prediction modelling and multiple regression analysis carried out with these markers provided an
accurate prediction of age (R2 = 0.92, mean absolute error (MAE) = 4.6 years). However, applying machine
learning, and more speciﬁcally a generalised regression neural network model, the age prediction
signiﬁcantly improved (R2 = 0.96) with a MAE = 3.3 years for the training set and 4.4 years for a blind test
set of 231 cases. The machine learning approach used 16 CpG sites, located in 16 different genomic
regions, with the top 3 predictors of age belonged to the genes NHLRC1, SCGN and CSNK1D. The proposed
model was further tested using independent cohorts of 53 monozygotic twins (MAE = 7.1 years) and a
cohort of 1011 disease state individuals (MAE = 7.2 years). Furthermore, we highlighted the age markers’
potential applicability in samples other than blood by predicting age with similar accuracy in 265 saliva
samples (R2 = 0.96) with a MAE = 3.2 years (training set) and 4.0 years (blind test). In an attempt to create
a sensitive and accurate age prediction test, a next generation sequencing (NGS)-based method able to
quantify the methylation status of the selected 16 CpG sites was developed using the Illumina MiSeq1
platform. The method was validated using DNA standards of known methylation levels and the age
prediction accuracy has been initially assessed in a set of 46 whole blood samples. Although the resulted
prediction accuracy using the NGS data was lower compared to the original model (MAE = 7.5 years), it is
expected that future optimization of our strategy to account for technical variation as well as increasing
the sample size will improve both the prediction accuracy and reproducibility.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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proﬁling; nevertheless, extracting additional information regard-
ing the donor, such as chronological age, could provide signiﬁcant
investigative leads and prove very useful in police investigations.
For intelligence purposes, estimating the age of a recovered stain’s
donor could potentially narrow down the number of suspects,
especially in cases where an eyewitness is not available.
Over the last decades, research has shown that aging is a very
complex process inﬂuenced by various genetic, lifestyle and
environmental factors. It causes a variety of molecular modiﬁca-
tions and adjustments in tissues or organs that accumulate over anss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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expression alterations [2] and variations at the DNA level [3,4].
Although there have been various approaches to estimate age at
death in human remains or chronological age in living individuals
[5,6], most of these attempts show limitations including low
sensitivity and prediction accuracy as well as lack of stand-
ardisation, restraining their applicability in crime scene samples.
Undoubtedly, developing an age prediction test is a major
challenge for forensic scientists since they would need to be able
to apply and validate it using minute or degraded samples
consisting of a range of tissues and body ﬂuids. As a ﬁrst step, the
generation of reliable age prediction models is a necessity.
It is believed that epigenetic analysis could serve as an
alternative or supplementary method to existing approaches since
particularly DNA methylation is well-known to be one of the
mechanisms responsible for cell differentiation and the cellular
response to aging [7,8]. It is generally suggested that there is an
increase in global epigenetic drift with age [9] and various
genome-wide methylation analyses have revealed a substantial
decrease in global DNA methylation levels with advancing age [10].
Changes in DNA methylation patterns due to aging are quickly
observed during the ﬁrst months of an individual’s life and
throughout childhood [11,12]. Cumulative evidence points towards
the distinct contributions of genetic [13], environmental [14,15]
and stochastic factors to DNA methylation levels at single genomic
areas. In order to identify speciﬁc age-associated differentially
methylated CpG sites for a particular body ﬂuid, scientists have
chosen to perform genome-wide studies [7,16–20]. Interestingly,
>95% of the associated sites were located within 500 bp of the
transcriptional start site of the associated gene, implying a
connection with regulation of gene expression [16].
From an intelligence perspective, it would be very advantageous
to translate observed biological age-associated DNA methylation
differences in a way that the chronological age of an individual is
revealed through an age prediction model. Overall, current
methodologies for methylation analysis can be divided into
genome-wide or gene-speciﬁc depending on the number of CpG
sites being investigated. As an example, following analysis of >650
whole blood samples from individuals aged 19–101 years using a
genome-wide approach, Hannum et al. built a quantitative model
using 71 highly age-predictive markers with a correlation between
true and predicted age of 0.96 and an average error of 3.9 years [21].
However, it should be emphasised that each tissue or body ﬂuid
could show a different age-associated DNA methylation pattern;
therefore, predicting age across a broad spectrum of human tissues
and cell types could be a very challenging task. Testing 13 different
cell types, Kock and Wagner [22] proposed a set of 5 CpG sites,
however the precision of their model was slightly lower (mean error
of 9.3 years). While the genome-wide DNA methylation arrays are
considered as the best tool during the discovery phase of potential
age-associated CpG sites, targeted sequencing is also required to
validate any association. Replicating the detected methylation levels
is necessary to conﬁrm the utility of the selected CpG sites and assess
their performance in a different dataset. From a forensic perspective,
the main challenge to be faced is the low quality and quantity of
forensic specimens, making it impossible to implement such age
prediction models (based on hundreds of markers) in forensic
casework in their current form. Therefore, developing an accurate,
robust and sensitive method that can analyse the proposed CpG sites
in forensic-type samples is essential.
In an attempt to narrow down the number of markers needed
for accurate prediction, Weidner et al. [23] performed a
comprehensive analysis of blood methylation proﬁles and found
that the methylation levels of only 3 CpGs – located in the integrin,
alpha 2b (ITGA2B), aspartoacylase (ASPA) and phosphodiesterase
4C, cAMP speciﬁc (PDE4C) genes – were substantial to create anepigenetic-aging-signature with a mean absolute deviation (MAD)
from chronological age of 5.4 years (RMSE = 7.2 years). Within the
forensic ﬁeld, recent age prediction models based on a small
number of CpG sites have also been studied, mainly in blood [24–
30], but also in other tissues such as saliva [31], semen [32] and
teeth [33]. However, most of these models are based on a limited
number of individuals and some still lack validation in an
independent cohort of samples. The reported mean prediction
errors range between 4–8 years (especially in validation sets where
available), suggesting that current tools allow for the prediction of
an individual’s decade (for example, the blood belongs to someone
in their 30s) rather than an accurate prediction outcome. In this
study, in an attempt to minimise the prediction error and increase
model accuracy, the potential of artiﬁcial neural networks (ANN)
was explored together with regression analysis. ANNs are a group
of machine learning algorithms inspired by biological systems and
have previously been used successfully to ﬁnd underlying trends in
complex datasets. There are various types of ANNs and the best
type to be used depends on the application. Normally, ANNs
consist of discrete layers; the ﬁrst is the input layer, which contains
the dependent variables (i.e. methylation data from age-depen-
dent CpG sites). Each of these variables are connected to a middle
layer via an optimised number of ‘nodes’, which, in turn,
interconnect all inputs to each other and eventually to the third
layer containing the designated output variable (i.e. age in years).
During the learning process, ANNs generally aim to minimise the
error in output estimations by systematically optimising the
connective weights between the nodes within the network. Given
their ability to learn holistically and often in a non-linear fashion,
ANNs have been extensively studied and applied in a range of other
applications [34,35].
Also, while most of these studies are based on targeted
methylation detection via pyrosequencing, qPCR [36], melting
curve analysis [37] and the EpiTYPER system [38,39] have also
been used. Although pyrosequencing has been the gold standard
for such analysis since its introduction [40,41] and shows various
advantages over other methylation techniques [42], it is mainly
performed as single reactions because multiplex pyrosequencing
can be complex [43]. In this study we also address the question of
whether a methylation assay based on benchtop next-generation
sequencing (NGS) of a small number of CpG sites could not only
provide focused 5-methylcytosine quantiﬁcation with base reso-
lution, but also allow for a sensitive and less costly age prediction
approach with similar accuracy to genome-wide DNA methylation
proﬁling approaches that could be applied in a forensic setting.
Towards achieving this aim, we pooled publicly available DNA
methylation proﬁles derived from whole blood samples to
investigate a subset of 45 previously reported age-associated
CpGs, which belong to 45 different genomic locations/genes, in an
attempt to identify those displaying the highest correlation with
age. Following multivariate, linear regression and ANN analysis, we
identiﬁed an epigenetic aging signature based on the methylation
status of a total of 16 CpG sites. To allow for reliable age predictions,
a next-generation sequencing protocol based on Illumina’s MiSeq1
platform was developed and optimised using commercially
available DNA methylation standards. To the best of our
knowledge, this is the ﬁrst study that uses machine learning, via
ANNs, together with an NGS-based DNA methylation detection
method for forensic age prediction.
2. Materials and methods
2.1. Description of genome-wide DNA methylation data sets
Genome-wide proﬁling has led to a more comprehensive
understanding of gene regulation epigenetic mechanisms.
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most commonly used genome-wide methylation platforms that
allows for simultaneous measurement of the methylation status of
27,578 (27 K chip) or 482,421 (450 K chip) CpG sites in the genome
at single nucleotide resolution. Thousands of samples have been
assayed using this platform in the literature and researchers have
made some of these genome-wide methylation data available in
online databases such as the National Center for Biotechnology
Information Gene Expression Omnibus (GEO).
In order to build the age prediction model, data from a total of
1156 whole blood samples were collected from individuals aged
between 2 and 90 years old and from various ethnic backgrounds
(mean age = 44) from seven genome-wide DNA methylation
studies summarised in Table S1 [12,16,17,19,21,44]. Methylation
data gathered from individual blood cell types such as peripheral
blood mononuclear cells (PBMCs) or CD4+ cells were avoided since
the ultimate aim of this research was to predict age from whole
blood stains. Samples were carefully collected so that there was an
equal representation of samples for all age groups, aiming for
100–150 samples per decade (see Fig. S1). The gathered samples
were either healthy control volunteers in studies investigating
DNA methylation changes of various diseases (usually above 40
years old) or were part of studies investigating epigenetic effects of
aging (usually either very young or very old), hence collecting
sufﬁcient samples of ‘middle’ age (particularly 30–40 years old)
was quite challenging. Additionally, even though the dataset
included roughly equal numbers of both females and males (597
and 559 respectively), there was an uneven gender distribution
within speciﬁc age groups due to the selected studies’ design
(Fig. S1). However, it was concluded that this should not affect age
prediction since none of the sex-speciﬁc differentially methylated
CpG sites previously reported in the literature, following analysis
with Illumina’s 27 K platform, were included in the group of
selected markers in this study [44].
Following the development of age prediction models, environ-
mental inﬂuences on age prediction were further investigated
using an independent cohort of healthy blood samples comprising
of 53 female monozygotic twin pairs collected from two genome-
wide studies [7,45] (Table S1). Secondly, to test the robustness of
the selected age-associated CpG sites when applied to body ﬂuids
other than blood, methylation data from 265 saliva samples was
collected from two different studies [46,47] (Table S1). One key
limitation when building a model for body ﬂuids other than blood
is the scarcity of non-blood based genome-wide studies that are
both run on one of the Illumina platforms and include information
regarding the volunteers’ age. Finally, according to Horvath [48]
the correlation between the observed and expected age in cancer/
diseased tissues was generally weak as there was evidence of
signiﬁcant biological age acceleration in most patients included in
his study (n = 5826). However, since there is usually no information
regarding possible disease status in a forensic blood sample of
unknown origin, it is important that the proposed age prediction
model can be universally applied. To assess potential variability in
age prediction, a data set including blood samples from a total of
1011 (577 females and 434 males) individuals aged 17–91 years
suffering from various diseases and cancers analysed on Illumina’s
27 K or 450 K platforms was analysed [8,17,19,49–52] (Table S2).
In each dataset, the DNA methylation value of each CpG site is
calculated as a beta (b) value, which is interpreted as the average
methylation for a particular site taking into account all cells
forming a body ﬂuid sample. Beta values can range from 0,
representing the unmethylated sites to 1, corresponding to those
completely methylated. Prior to analysis, genome-wide DNA
methylation datasets underwent a quality control analysis to
account for common experimental biases, such as batch effects
using the IBM SPSS v.22 software. Therefore, we used overall meandetected methylation levels to normalise the methylation levels
between different datasets, but without removing the occurring
DNA methylation variation, partly explained by age. We used the
normalised methylation values for age prediction analysis.
2.2. Selection of potential age-associated CpG sites
The ability to accurately predict age regardless of the tissue type
would be very advantageous in criminal investigations where the
identiﬁcation of the tissue source of a sample is often challenging.
Even if the purpose of this study was to identify age-associated CpG
sites in blood, the ability to apply a potential model in other tissues
with similar accuracy would save both time and resources. In an
attempt to select more robust age-associated differentially-
methylated markers across tissues, the study by Horvath [48]
was chosen as the most appropriate. The author built an age
prediction model applicable in various tissues using a total of 353
markers, which were categorised by a coefﬁcient value (ranging
from 1.719 to 3.067) that relates the CpG sites to a transformed
version of age. In order to cover all potential correlations with age
and maximise the chance of selecting suitable markers, 45 CpG
sites from the 353 marker pool included in Hovarth’s model were
selected, speciﬁcally this included those displaying the highest
(positive/negative) coefﬁcients (Table S3). Their chromosomal
location was conﬁrmed using the Ensembl genome browser; most
are located within or near a gene. While it has previously been
demonstrated that the ELOVL2 marker can be a good predictor of
chronological age in blood [24], there is an absence of genome-
wide data for the relevant CpG sites, hence these sites could not be
included in this study.
2.3. Statistical analysis
Statistical analysis was performed using STATISTICA software
v.13.1 (StatSoft Inc., 2014, Oklahome, United States). To assess data
distribution, the minimum, maximum, mean and standard
deviation (SD) were calculated. Hypothesis testing was evaluated
by calculating p-values with a signiﬁcance cut-off of 0.05.
Multivariate analysis was used to assess if other deﬁned factors
in the datasets (such as sex) were signiﬁcantly associated with age.
The degree of linear association between methylation levels and
chronological age was measured by calculating the correlation
coefﬁcient (r), while a general regression model, implemented
using a forward stepwise approach, was used to assess the
accuracy of age prediction with the selected marker candidates.
The ﬁtted regression line explains a proportion of the variability in
the dependent variable (y) and the residuals indicate the amount of
unexplained variability. The proportion of the total variation
explained by the model was also assessed by the goodness-of-ﬁt of
the line (R2 value). In some cases, regression lines were linear but
there were cases where the relationship between two variables
was curved revealing non-linear relationships. For example, in
methylation quantiﬁcation by bisulﬁte PCR the polynomial
regression was often observed either as quadratic curves (y = ax2 +
bx + c) or cubic curves (y = ax3 + bx2 + cx + d).
2.4. Artiﬁcial neural network (ANN) modelling
The age-speciﬁc CpG site methylation data was used to build,
train and test a suitable ANN for chronological age prediction. In
this study, several ANN types including 2- and 3-layer multi-layer
perceptrons (MLPs), radial basis functions (RBFs), probabilistic
neural networks (PNNs) and generalised regression neural net-
works (GRNNs) were built and their performance critically
evaluated using Trajan v6 software (Trajan Software Ltd.,
Lincolnshire, UK). Brieﬂy, optimisation of each ANN type and
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variables (45 selected age-associated CpG sites) were included in
the initial design phase to elucidate which ANN model type was
likely to be most applicable to age prediction. Following this, the
most promising network type (GRNN) was optimised further in a
series of stages. GRNNs are a type of ANN that use a combination of
a radial basis and linear functions to perform the output estimation
[53]. The ﬁrst optimisation stage was performed to ﬁnalise training
and veriﬁcation dataset proportions by assessing the performance
of the mean inaccuracy of the blind test sets. Depending on the
application, between 50% and 70% of the full 1156 cases were
assigned as training cases with equal splitting of the remaining
proportion between veriﬁcation and blind test cases. This was
repeated several times for each proportion value and with random
assignment of cases for training, veriﬁcation and testing every
time. The network designer tool was set to balance GRNN
veriﬁcation set errors against network diversity to cover as many
architectures as possible across all model types. In total, 108
architectures were investigated in each stage and 50 of the best
GRNN networks were ranked by correlation and output error
separately for the training, veriﬁcation and blind test datasets. In
Stage 2, advanced random sampling was applied whereby training
and veriﬁcation cases were assigned as per the best performing
GRNN architecture from Stage 1, but blind test cases were ﬁxed. In
Stage 3, the reproducibility of ten replicates of the model was
assessed by selecting the best GRNN from Stage 2 and ﬁxing all
training, veriﬁcation and blind test subsets and the best model
overall was then selected from this pool. The variability in age
estimations for all subsets across all replicate GRNN models was
then expressed as mean error  one standard deviation. Following
this, all ten networks were each subjected to a sensitivity analysis
to assess the relative contribution of each CpG site input to model
accuracy. The error ratio was calculated as the ratio of the observed
GRNN test error using all variables to the error obtained when eachTable 1
Designed bisulﬁte PCR assays.
CpG site Gene Primer Sequence (
cg19761273 CSNK1D F 
R 
cg27544190 C21orf63 F 
R 
cg03286783 CASC4 F 
R 
cg01511567 SSRP1 F 
R 
cg07158339 FXN F 
R 
cg05442902 P2RXL1 F 
R 
cg24450312 RASSF5 F 
R 
cg17274064 ERG F 
R 
cg02085507 TRIP10 F 
R 
cg20692569 FZD9 F 
R 
cg04528819 KLF14 F 
R 
cg08370996 NR2F2 F 
R 
cg04084157 VGF F 
R 
cg22736354 NHLRC1 F 
R 
cg06493994 SCGN F 
R 
cg02479575 C19orf30 F 
R variable was systematically removed. Larger error ratio values
represented more network dependency on that speciﬁc CpG site
variable. All input variables were also assessed for collinearity
using SPSS Statistics v23 (IBM Corporation, New York, USA).
2.5. Body ﬂuid samples and DNA preparation
A set of whole blood samples were collected to test the
developed ANN model with the proposed methodology. The
present study was carried out following full ethical approval by
King’s College London Biomedical Sciences, Dentistry, Medicine
and Natural & Mathematical Sciences Research Ethics Subcommit-
tee (BDM/13/14-30). Full informed consent was obtained from the
donors or their parents in case of under-aged individuals prior to
collection. Whole blood was collected from a total of 46 individuals
aged 11–76 years old coming from various ethnic backgrounds.
Genomic DNA was isolated from 200 ml of whole blood using the
BioRobot EZ1 DNA blood kit (QIAGEN, Hilden, Germany). Following
puriﬁcation, samples were quantiﬁed using the Quantiﬁler Human
DNA Quantiﬁcation kit (Applied Biosystems, Foster City, United
States). 500 ng of each DNA sample was used for bisulﬁte
conversion using the MethylEdge Bisulﬁte Conversion system
(Promega, Madison, United States) and bisulﬁte-treated DNA was
eluted in 20 ml of elution buffer. For control and linearity analysis, a
set of DNA standards of known methylation levels ranging from 0%
to 100% (EpigenDx, Hopkinton, United States) were used.
2.6. Bisulﬁte PCRs
In this study the online Ensembl genome browser (GRCh37/
hg19) genome was used to obtain the required genetic information
for assay design. Primers were designed to speciﬁcally amplify
bisulphite-treated DNA using the online-tool BiSearch [54] and
design parameters were adjusted to account for the generally low50-30) Amplicon Length (bp)
TGTTTAGTTTGAAGATTGAG 150
CCTTATTTCCTTTACAAAAA
GGGTAGGATTAAAGTTGA 106
CTTAAAAATAACAATCCCC
GTTTTAGTTAGTGGGTG 181
CCCCTCCTCAAATCAAA
TATTAGATTTAGTATAGGGG 132
CCCACAACTATTCAAATA
GGAATATGTTTTGTTTAAAA 122
TAATTAACCTCTCTATACCT
GTATGTTTTGGTTTTTGT 109
AATAACCTCTAAACTAACC
GTTATTTATAGAGTTTGAG 201
TCTACTACAAACCAAA
AGGGAATAAGTATTTTTT 139
CTCACAATCAAACTTCTATATAC
GTTAATGGATTTGGTTTTG 186
AACTCAAAAAATCCTTCCT
TTGTTGTTGTGGTAGT 160
AACCCAACAAATTAAA
AATAGGTTTTGGTGTAGTT 138
CAACCTCTAATAAATTCTCT
GTGTTAAAGTTTATTATATAGA 187
AAAAAAAAAAACACACAC
GAGGGTGTTTGTTTTTTT 111
AACATTTCATTCATTCATTC
GTTGAGTTTAGGAGTTTTAT 201
CTTTAAAAAATTTAACCACC
GGAGAGTAAGTTAAGAAATA 150
AACCTACCAAAAACCAAC
GGAGGAGAATGTTATTTATT 143
CTATCCAAAATTCTAAAAAC
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to the T-richness of the bisulphite-treated DNA sequences. A total
of 16 singleplex assays were designed to investigate the selected
age-associated CpG sites; each bisulﬁte PCR assay includes a PCR
primer set (forward and reverse), none of which binds to areas
containing other CpG sites to avoid potential bias (Table 1).
Information on the obtained amplicons including their chromo-
somal location and number of included bisulﬁte-conversion
controls and CpG sites are presented in Table S4. Although the
assays were primarily designed to interrogate the 16 selected CpG
sites, sequencing of the entire PCR product on the MiSeq1 platform
(Illumina, San Diego, United States) allowed for the co-analysis of
all adjacent CpG sites included in the fragment. Brieﬂy, PCRs were
carried out in 13 ml reaction volumes containing a ﬁnal concen-
tration of 1X ZymoTaq premix (Zymo Research, Irvine, United
States), 3.2 mM MgCl2, 0.4 mM forward and reverse primers, with
the addition of 1 ml of bisulﬁte DNA template. The thermocycling
program used was: 95 C for 10 min, followed by 30 cycles of 94 C
for 30 s, Tm for 30 s, 72 C for 30 s, and a ﬁnal extension step of 72 C
for 7 min. The optimised Tm was as follows: 48 C for cg07158339,
cg17274064, cg02085507, cg20692569 and cg02479575, 50 C for
cg19761273, cg27544190, cg01511567, cg24450312 and
cg04528819 and 52 C for cg03286783, cg05442902,
cg08370996, cg04084157, cg22736354, cg06493994. Following
ampliﬁcation, the quality of PCR products was assessed on a 2%
agarose gel if necessary.
2.7. Next generation sequencing using illumina MiSeq1
Singleplex PCR products were pooled together and puriﬁed
using the MinElute PCR puriﬁcation kit (QIAGEN) in 16 ml of
DNase-free water. Prior to library preparation, all puriﬁed samples
were quantiﬁed using the Qubit dsDNA HS Assay kit (Invitrogen,
Carlsbad, United States) according to the manufacturer’s instruc-
tions and in combination with the Qubit 2.0 Fluorometer
instrument. Pooled PCR products were diluted appropriately to
provide 50 ng of ampliﬁed DNA within 25 ml. Library preparation
was performed using the KAPA Hyper Prep kit for Illumina (Kapa
Biosystems, Wilmington, United States) with half volume reac-
tions. Library ampliﬁcation proceeded with 8 cycles while the
clean-up steps were performed using the AMPure XP Beads
(Beckman Coulter Genomics, Danvers, United States) and the
Illumina Resuspension buffer (Illumina). To assess libraries’
quantity, puriﬁed libraries were diluted 1:4000 in DNase-free
water and quantiﬁed using the KAPA Library Quantiﬁcation Kit for
Illumina platforms (Kapa Biosystems). Indexed DNA libraries were
then normalised to 4 nM using Tris-HCL 10 mM/pH 8.5 with 0.1%
Tween and were pooled together to a ﬁnal volume of 240 ml. Using
freshly made 0.2N NaOH, 5 ml of pooled libraries were denatured
and, through dilution with pre-chilled Hybridisation buffer (HT1,
Illumina), a 10pM library was obtained. Finally, 13% diluted PhiX
control (80 ml) was added to the library and sequencing was
performed using the 300-cycle MiSeq1 reagent v2 cartridge
(Illumina). The preparation of the ﬂow cell and the set-up of the
instrument were performed per manufacturer’s instructions. It
should be noted that the instrument was set up to run a paired-end
read of 150 bp of DNA sequence from both ends of the library
products. Auto analysis was set up as a FASTQ-only method.
Following auto-analysis by the MiSeq1 Reporter Software,
which separated the millions of generated sequences into the
constituent samples on the basis of the ligated adaptor tags,
collated sequences were packaged in a text-based format (FASTQ
ﬁles). For alignment, we used a custom bisulﬁte-converted
reference genome containing all analysed DNA sequences, which
is quicker and more user-friendly compared to available align-
ments using the entire genome. Sequences within these FASTQﬁles were aligned using a Burrows-Wheeler alignment (BWA)
algorithm. This process was implemented in the BWA program [55]
using the maximum entropy method (mem) algorithm that
matched the sequences generated to the respective methylation
marker (i.e. a sequence obtained from the PCR product of any
speciﬁc marker would be most similar to the reference sequence
for that marker, and hence the software would align this sequence
with that marker). Therefore, the millions of sequences contained
within the FASTQ ﬁle can be associated with their respective
marker, giving potentially hundreds of thousands of individual
sequences all aligned in parallel to a speciﬁc reference sequence/
marker. At the conclusion of this alignment process, a sequence
alignment/map (SAM) ﬁle was produced, which was further
modiﬁed using SAMtools [56] to facilitate the conversion into a
BAM ﬁle. The Genome Analysis Toolkit (GATK) [57] was
subsequently used to interrogate this BAM ﬁle by targeting
speciﬁc positions in these aligned sequences (i.e. each CpG site)
and reporting the number of sequences containing a C and the
number of sequences containing a T at this position. In this way it
was possible to assess the methylation state at every studied CpG
site. The uniﬁed genotyper algorithm was employed within GATK
to produce these genotype data for each CpG site, which were
written into a variant call format (vcf) ﬁle that could subsequently
be manipulated in Excel. The Integrative Genomics Viewer
software (IGV) was used for visualisation and veriﬁcation of the
alignment. While in most cases the bisulﬁte conversion rates were
>99%, methylation values were ‘corrected’ by taking into account
the mean bisulﬁte conversion rates per fragment calculated by the
built-in conversion controls (non-CpG cytosines). The obtained
methylation values for each CpG site were further normalised
using the resulting equations of standard curves created from
known DNA methylation standards. Lastly, to account for potential
methodology-dependent differences, the NGS derived methylation
values were normalised to the genome-wide data, used to build the
prediction model, by applying the method previously described
when normalising the different genome-wide data sets.
3. Results and discussion
3.1. Age-associated DNA methylation changes in blood
Using publicly available DNA methylation databases, normal-
ised beta values for the selected 45 CpG sites were gathered for a
total of 1156 whole blood samples from individuals 2–90 years old.
Methylation fractions (zero to one) were compared against the
actual age of each individual in order to investigate potential
correlation between methylation levels and age (example graphs
for 16 out of 45 CpGs are presented in Fig. 1). As expected, some
CpG sites showed greater variation than others; for example,
cg07455279 (NDUFA3) demonstrated the largest methylation
range (difference between the lowest and highest detected
methylation value for each marker) (0.815) while cg05442902
(P2RXL1) usually showed low methylation levels (<0.387). In
general, the methylation of certain CpG sites such as cg19761273
(CSNK1D), cg01511567 (SSRP1), cg07158339 (FXN) and
cg05442902 (P2RXL1) was clearly decreasing with advancing
age, while others, cg20692569 (FZD9), cg04528819 (KLF14),
cg04084157 (VGF) and cg22736354 (NHLRC1) to name but a
few, were increasingly methylated over time. These observations
align with the age relationship that Horvath reported in his study
[48].
3.2. Identiﬁcation of the epigenetic aging signature
The observed age-associated methylation changes for all
markers were assessed for their statistical signiﬁcance in an
Fig. 1. Change of methylation levels over advancing age for the 16 CpG sites included in the eventual ANN model.
230 A. Vidaki et al. / Forensic Science International: Genetics 28 (2017) 225–236attempt to identify those sites that could form the proposed
epigenetic-aging-signature. Firstly, using multivariate analysis and
testing for the effect of gender and ethnicity on age-associated
methylation, no signiﬁcant correlation was determined (p = 0.77
and p = 0.09 respectively). Using linear regression analysis, a
signiﬁcant correlation between methylation levels and age (p
< 0.05) was conﬁrmed for 25 out of the 45 CpG sites (Table S5).
Applying stepwise multiple linear regression for variable selection,
we obtained similar results regarding the importance and order of
markers (Table S6). In order to perform this type of analysis, the
markers were added one by one into the age prediction model until
there was no statistical improvement. As a result, the use of 23 CpG
sites resulted in a value of R2 = 0.923, which was not further
improved with the addition of more markers. All 23 age-associated
CpG sites revealed following stepwise regression are included in
the set of markers identiﬁed after individual linear regressionanalysis. In both analyses cg22736354 (NHLRC1) was found to be
the most important. Interestingly, while cg07455279 (NDUFA3)
had demonstrated the higher methylation range, it did not
demonstrate a statistically signiﬁcant correlation with age, which
mirrors the complexity and high, inter-individually variable nature
of methylation patterns.
Applying multiple linear regression analysis on the methylation
values of all 1156 individuals for the 23 age-associated CpG sites,
the correlation between ﬁtted and true age was strong (linear
correlation, R2 = 0.923), while the mean absolute age modelling
error using all data was 4.61 years (standard deviation = 4.36 years)
(Fig. 2a). In a brief summary, 61% (700/1156) of individuals were
ﬁtted within a 5 year error range, while 89% (1029/1156) of
samples were ﬁtted within a 10 year error range. Multivariate
regression was mainly applied to explore the relationship between
DNA methylation patterns and age, but also revealed that none of
Fig. 2. Age prediction using multiple regression analysis (23 CpG sites) (a) Predicted vs. Chronological age (years) for all 1156 individuals used in this study (linear correlation
R2 = 0.923, mean absolute error = 4.61 years, standard deviation = 4.36 years), (b) Predicted error (years) over advancing age. As shown most individuals were predicted within
a 5 year error range (0.61), while 1029 out of 1156 samples were predicted within a 10 year error range (0.89).
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associated DNA methylation patterns in a statistically signiﬁcant
way. While there were individuals that seemed to age fast, there
were also others that were ﬁtted as much younger (Fig. 2b).
Notably, the error in older individuals (>60 years old) was higher
compared to younger ones, which is not only expected as older
individuals have been exposed to more environmental stress
throughout their lifetime that could have potentially caused
changes in DNA methylation patterns (epigenetic drift), but has
also been observed before in previous models [25,33].
3.3. Age predictions from blood using artiﬁcial neural networks
Neural network models showed that the prediction accuracy
could be signiﬁcantly improved over multiple linear regression
models. It is believed that ANN models have the ability to recognise
complex patterns, which are often observed in complex traits like
chronological age. The best model (Fig. 3a) was a 16-694-2-1
GRNN-type model, which was built on a 60:20:20 training,
veriﬁcation and blind test set dataset proportion (optimised).
The average absolute errors and standard deviations in each of
these subsets were 3.3  3.0, 4.6  3.5, and 4.4  3.6 years,
respectively (Fig. 3b). As a whole, a correlation between predicted
and true age of R2 > 0.96 was achieved across all subsets with an
average absolute error of 3.8  3.3 years. The correlation for the
blind test set (R2 = 0.95) was consistent with both the training and
veriﬁcation sets showing that the model could generalise very
well. For the blind test set in particular, the 75th percentile of all
231 case errors lay within 6.3 years. This performance is consistent
with other ANN-based applications from our research group which
revealed a 3–5% average inaccuracy across predictions [58] and
with a recent study reporting a percentage of prediction error of
6.3% [38].
This ANN model used data from 16 of the CpG sites, all 16 of
these sites having also been identiﬁed in the stepwise multiple
regression analysis: the methylation changes over time for these 16
markers are illustrated in Fig. 1. While a distinct methylation trend
is observed in all cases, there are occasional samples that
demonstrate an ‘unusual’ methylation status for a few CpG sites.
This can be explained either as natural inter-individual variation or
as a result of a ‘unique’/personalised environment that couldinﬂuence the methylation of these particular sites. Of course,
technical variation cannot be excluded, however efforts were made
to take this into account and normalise the data before analysis.
Information regarding the genes that the CpG sites lay near or
within was acquired to identify their function and potential
involvement in aging. The exact chromosomal locations of the CpG
sites as well as the involved genes are shown in Table 2.
As expected, all markers showing signiﬁcant correlation with
age belong to genes involved in age-related processes and
conditions; a few examples are presented here. cg19761273 is
associated with CSNK1D, which is a serine-threonine protein
kinase involved in essential cell pathways including circadian
rhythms and DNA repair. It is believed that CSNK1D has a role in
arranging the microtubule network during mitosis to prevent DNA
damage [59]. On the same theme, SSRP1 linked with cg01511567
seems to be crucial to anticancer mechanisms since it forms a
transcriptional factor that interacts speciﬁcally with histones and
prevents DNA damage [60]. Additionally, cg03286783 belongs to
the CASC4 gene, increased expression levels of which have been
found in breast and ovarian cancers [61]. Moreover, cg05442902 is
associated with the P2RXL1 gene known for its involvement in
inﬂammatory and immune processes, all affected by aging [62]. A
recent study has also linked TRIP10 gene (cg02085507) with the
regulation of cancer cell growth; in fact differential DNA
methylation of this gene has been suggested to promote cell
survival or death [63]. Additionally, cg04528819 belongs to
transcription factor KLF14, which is known as the ‘master
regulator’ of obesity and other metabolic traits [64]. Lastly, the
nerve growth factor VGF associated with cg04084157 has been
linked with altered expression levels in the age-associated
Alzheimer’s disease [65]. Even though some of the genes are
associated with age-related diseases, Fig. 1 demonstrates a gradual
and consistent methylation increase or decrease over time at these
particular CpG sites; therefore, their detected correlation with age
should not be linked with effects due to these individuals being
affected by age-related conditions.
The residual error obtained by the GRNN (Fig. 3b) displayed a
distinct, imbalanced pattern in comparison to that obtained from
multiple regression analysis (Fig. 2b), which was more randomly
distributed around the mean. Residual errors obtained by the
GRNN for old individuals (>60 years old) revealed a different
Fig. 3. Summary of ANN model for age prediction analysis. (a) Predicted vs. Chronological age for all 1156 individuals included in the study using the optimised 16–694-2-1
GRNN model, (b) Residual errors for the optimised model, (c) Prediction skewness for the blind test cases only using the optimised model, and (d) Sensitivity analysis and
marker input consistency to age predictions across training, veriﬁcation and blind test subsets. Error ratios are calculated as the ratio of the prediction inaccuracy by including
all inputs to the prediction accuracy following systematic removal of each CpG site from 10 replicated GRNN networks. Boxes include data from the 25th–75th percentile as
well as the median (thin line) and mean (thick line); error bars include the 5th and 95th percentile; numbers over boxes represent the rank order based on the mean.
232 A. Vidaki et al. / Forensic Science International: Genetics 28 (2017) 225–236grouping within the graph as the model tends to underestimate
their age. These ﬁndings could indicate that there is a potential
ANN bias in age prediction within speciﬁc age groups, that could
perhaps be corrected in the future, or that there is a learning
artefact due to so many different study datasets being combined.
Lastly, the skewness of the blind test predictions alone showed that
there was a marginal bias towards under-prediction of age using
the GRNN model (Fig. 3c). In an attempt to further understand the
relative contribution and consistency of each CpG site variable for
age prediction, ten replicate GRNNs were generated. Sensitivity
analysis showed that all error ratios lay above 1.0 meaning that
they all contributed to the model positively (Fig. 3d). Most notably,
cg22736354 (NHLRC1) and cg06493994 (SCGN) contributed the
most to prediction, which was also true for the former in the
stepwise regression analysis. Some moderate collinearity existedbetween these two variables and so the relative ranking of either
should be considered carefully (variable inﬂation factors were
6.172 and 7.743 respectively, see Table S7 & S8), which has also
been observed in previous models [38]. Overall, it was decided not
to remove either variable from the network as predictions became
worse overall, even after re-training. From the third highest ranked
variable (cg19761273, CSNK1D) onwards, no severe collinearity
existed and therefore these rankings were more reliable. Despite
contributing to the prediction in a minor way (error ratio = 1.0127),
cg03286783 (CASC4) was the lowest ranked of all 16 variables
across all replicate GRNNs. Consistency of contribution across all
ten GRNNs was also acceptable and in general error ratios varied
<0.1 units for 25th–75th percentile of all data.
Considering that a similar prediction accuracy was observed
when using 353 CpG sites in Horvath’s study (age correlation of
Table 2
Epigenetic aging signature consisted of 16 CpG sites Information in this table includes the exact chromosomal location of the selected CpG sites (GRCh37/hg19) as well as the
involved genes.
CpG sites Chromosomal location Gene
cg19761273 17: 80,232,096 CSNK1D  casein kinase 1; delta isoform 1
cg27544190 21: 33,785,434 C21orf63  chromosome 21 open reading frame 63
cg03286783 15: 44,580,973 CASC4  cancer susceptibility candidate 4 isoform a
cg01511567 11: 57,103,631 SSRP1  structure speciﬁc recognition protein 1
cg07158339 9: 71,650,237 FXN frataxin, mitochondrial isoform 1 preproprotein
cg05442902 22: 21,369,010 P2RXL1  purinergic receptor P2X-like 1; orphan receptor
cg24450312 1: 206,681,158 RASSF5  Ras association domain family 5 isoform B
cg17274064 21: 40,033,892 ERG  v-ets erythroblastosis virus E26 oncogene like isoform 2
cg02085507 19: 6,739,192 TRIP10  thyroid hormone receptor interactor 10
cg20692569 7: 72,848,481 FZD9  frizzled 9
cg04528819 7: 130,418,315 KLF14  Kruppel-like factor 14
cg08370996 15: 96,874,031 NR2F2  nuclear receptor subfamily 2; group F; member 2
cg04084157 7: 100,809,049 VGF  nerve growth factor inducible precursor
cg22736354 6: 18,122,719 NHLRC1  malin
cg06493994 6: 25,652,602 SCGN  secretagogin precursor
cg02479575 19: 4,769,653 C19orf30  hypothetical protein LOC284424
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high accuracy using a smaller number of CpG sites (16 in our case)
was possible (mean absolute error of 4.4 years in the blind test set).
This is also supported by previous studies where researchers
obtained mean prediction errors of 4–8 years in their validation
tests, such as 5.1 years using 8 markers by Zubakov et al. [39], 6.9
years using 3 markers by Park et al. [30], 4.2 years using 7 markers
by Freire-Aradas et al. [38], 3.9 years using 5 markers by Zbiec-
Piekarska et al. [25], to name but a few. To the best of our
knowledge, only one of the proposed 16 age-associated genes in
our study has been used before in a forensic age model (more
speciﬁcally, KLF14 is included in the Zbiec-Piekarska model),
therefore contributing towards building a bank of potential
markers. As shown before, our model sensitivity analysis revealed
that there were markers contributing more to age prediction,
therefore, one could propose that by replacing or adding some of
the other ‘strong’, age-associated CpG sites reported in the
literature, such as the example of ELOVL2 locus [24], the resulting
prediction accuracy can be further improved. Also, for future
studies, one should also consider the combination of the best age-
associated CpG markers with other age-related molecules, like
mRNA, as this can also improve accuracy [39].
3.4. Validation through an independent cohort of monozygotic twins
Even though the model was applied to 231 blind test cases in
the model optimisation stage, it was important to externally test
model performance with an independent cohort of samples. For
this reason, we evaluated the optimised model using 106 blood
samples belonging to 53 monozygotic twin pairs aged 33–77 years.
Monozygotic twins were chosen since they begin life with nearly
identical genetic and epigenetic proﬁle and it is the effect of
various environmental factors that alters their genome-wide DNA
methylation proﬁle later in life. The methylation values of each
sample for all 16 CpG sites were imported into the model as a blind
test and the average mean absolute error was 7.07  5.78 years.
This higher prediction error could be partly explained by the fact
that most twins were old (mean age of 58 years in this dataset),
therefore the effect of environmental conditions and lifestyle
should be considered. Interestingly, between pairs there were
twins that were predicted to be either much older or much younger
than their actual age, but the prediction differences within twin
pairs (mean = 2.65  2.37 years) were not statistically signiﬁcant as
obtained by paired t-test analysis (p-value = 0.99). These results
can be interesting since they indicate some sort of systematic
inﬂuence of either the twins’ genetics or environment. According
to Horvath, while the heritability of age acceleration was found tobe 100% in new-borns, it was only 39% in older subjects suggesting
that non-genetic factors become more relevant later in life [48].
Also, although all twins were volunteered as healthy controls, it
would be beneﬁcial if information regarding disease status or
susceptibility was available, that could possibly partly explain
these results.
3.5. Effect of disease state on age predictions
It is important to bear in mind that, in contrast with a medical
setting, information regarding possible disease status is not
available when trying to predict chronological age from an
unknown bloodstain or sample during a criminal investigation.
Consequently, it is important to build a robust age prediction
model containing DNA methylation markers that would not show
differential methylation patterns due to disease states. However,
this might be extremely challenging to do. Therefore, although
Horvath has already reported that the predicted age from cancer
tissues correlated poorly with patient age in his study [48], we
aimed to investigate a set of diseased samples and the effect on age
prediction. For this purpose, seven datasets including diseased
samples were analysed in an attempt to further validate the
proposed age prediction model (Table S2). Fig. S2 shows the
predicted vs. chronological age for all 1011 samples; combining all
diseases together, a correlation of 0.74 and a mean absolute error of
7.18 years was obtained. However, when analysing separately
samples suffering from blood vs. non-blood related diseases it
becomes evident that the error is much higher for blood related
diseases (error = 12.74 years). This is of course expected since the
methylation data were gathered by analysing whole blood samples
and therefore the potential effect is direct. In more detail, the
obtained mean absolute errors for each disease were as follows:
type I diabetes – 8.63 years, anaemia – 14.38 years, bone marrow
disorders (including leukaemia) – 11.09 years, ovarian cancer –
7.45 years, breast cancer – 6.77 years and schizophrenia – 5.03
years.
Schizophrenia showed the lowest age prediction error, while
anaemia demonstrated the lower correlation with age. While
changes in expression of one of the markers included in the model
– cg04084157 (VGF) – have been detected in the cerebrospinal ﬂuid
of patients with different neurological and psychiatric conditions
such as schizophrenia [66], it did not seem to affect prediction in
blood. It should also be noted that schizophrenia patients
comprised the largest dataset; therefore a better prediction error
could also be due to the greater number of samples. On the other
hand, the results regarding anaemia (n = 28) come as no surprise
since anaemia is one of the most common blood disorders, which
Fig. 4. Age prediction in blood using the developed MiSeq method (n = 46).
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patterns, especially in blood. Interestingly, cg07158339 is located
near the FXN gene which has been associated with selectively and
non-covalently interacting with ferric ion Fe (III) to assemble the
iron-sulphur cluster [67]. Consequently, differential methylation
patterns due to the disease status in blood cannot be excluded.
Another example includes the ERG oncogene associated with
cg17274064, which is an erythroblast transformation-speciﬁc
transcription regulator typically mutated in myeloid leukaemia
[68]. As shown, the dataset comprised by various bone marrow
disorders including leukaemia demonstrated the second largest
mean error (11.09 years). Thus, by testing this limited range of
diseases, it seems that our model has the potential to perform quite
well in disease-stressed samples unless these are blood-related,
and the possibility of disease state should be taken into account
when attempting predictions.
3.6. Applying the age prediction model in saliva
In Horvath’s study, this set of 353 markers, which included our
16 CpG sites, were used to predict age in a wide range of other
tissues. However, individual marker capabilities should not be
overlooked, therefore to assess potential tissue-speciﬁc variations
in age prediction, the selected markers were also tested in a set of
saliva samples. Saliva is not only one of the most common types of
biological evidence found at crime scenes in the form of used
glasses, cigarette butts or stamps, but also was the only tissue
where sufﬁcient genome-wide methylation data was available for
robust analysis. One confounding factor when analysing saliva
methylation data is the variation derived from the collection
method used. Depending on the method applied to collect saliva
(for example by mouth wash, oral ﬂuid swab or by ‘touch’ samples),
the body ﬂuid stain might contain differing proportions of various
cell types (for example, buccal epithelial cells and white blood
cells), which can result in detecting variable DNA methylation
levels. Methylation values regarding the selected 16 CpG sites were
collected from a total of 265 samples of individuals aged 21–55
years; while 159 samples were used to train a GRNN model, 53
samples were used for each of the veriﬁcation and blind test sets.
As shown in Fig. S3, a good correlation of 0.73 was obtained
between predicted and true age, while the mean error was 3.18
years (training), 6.26 years (veriﬁcation) and 4 years (blind test).
The prediction accuracy was encouraging considering the size of
the dataset; however, the narrow age range (21–55 years) cannot
be ignored. Furthermore, saliva was collected and extracted
differently between the two studies used, which could introduce
further variation. The majority of saliva samples used here were
collected via the Oragene DNA collection kit, which can typically
result in DNA being extracted primarily from white blood cells,
rather than buccal epithelial cells; which, in this case, could
explain the high accuracy of obtained predictions. Again, as shown
in the graph representing the age residuals, age prediction seemed
to be more accurate in younger individuals, where underestimat-
ing age was not very common. Even though including more saliva-
speciﬁc age-associated CpG sites could signiﬁcantly improve the
obtained prediction error, these results highlight the potential
applicability of the proposed model in non-blood tissues.
3.7. Model validation by means of next generation sequencing
Our last goal in this study was to implement our age prediction
model by using an accurate, robust and sensitive method that can
analyse the proposed CpG sites in forensic-type samples.
Compared to previous analog methylation methods used for age
prediction analysis, we strongly believe that NGS can show great
potential, as not only it can be more sensitive and accurate, but canalso provide data of higher-resolution. Therefore, an NGS-based
protocol capable to detect DNA methylation differences in
bisulﬁte-converted DNA fragments was developed and adjusted
using a previously published method [69]. The overall perfor-
mance of the method was good including <0.05 standard deviation
in methylation detection for most markers, even though we
observed an imbalance between the average reads of the
investigated fragments; speciﬁcally, cg24450312 (RASSF5) and
cg17274064 (ERG) were the most challenging markers. This could
be due to different PCR efﬁciencies explained by DNA sequence
differences among markers, and can be improved in future
experiments. Nevertheless, to ensure accurate methylation quan-
tiﬁcation, a minimum of 1000 reads per marker was set. For
prediction analysis, a set of 46 blood samples from individuals aged
11–76 years old were analysed in triplicate using the proposed
method and their predicted age was calculated using the average as
a blind test in our age model. As a result, the age correlation taking
the ﬁnal normalised methylation data was 0.86 and we could
predict age with a mean absolute error of 7.45 years (Fig. 4).
These results are very encouraging, and even though the age
prediction accuracy is lower than that obtained in the model’s
blind test, for this sample set we are introducing an additional layer
of variation when normalising methylation values between totally
different detection systems (the NGS-derived methylation values
in the samples with the microarray-derived ones used to train the
model). As we aimed to investigate a representative population
sample, no information regarding the individuals’ health and
lifestyle were collected as this information would not be available
to a ‘standard’ forensic scenario. Since DNA methylation is known
to not only be age-speciﬁc but can also be inﬂuenced by diet [70],
lifestyle [71], smoking [14], ancestry [72] and other factors, we
cannot exclude that these factors could have affected the
methylation status of the selected sites in these individuals.
However, even if efforts were made to normalise the NGS data over
the genome-wide methylation data that the age prediction model
uses, we cannot also ignore other potential (PCR-introduced)
technical variation. Current experiments focus not only on
increasing the sample size to achieve a more representative
prediction accuracy, but also to analyse enough samples to re-train
the model with NGS data; the latter would eliminate any
methodological or technical variation. Furthermore, we are also
investigating the possibility of multiplexing the bisulﬁte PCRs to
allow for more sensitive analysis and validating the entire method
using forensically relevant criteria. We understand that both the
required high coverage (1000X) and triplicate analysis may be
impractical in routine forensic analysis, albeit less so for blood
traces where DNA is often, although not exclusively, found in
relatively high quantities. Future efforts should therefore also be
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ibility of the proposed NGS based method. We believe that
introducing an NGS-based solution for age prediction can provide
many advantages from a casework point of view, mainly due to its
high sensitivity, multiplexing capabilities and the potential for
merging with other DNA marker analysis. Nevertheless, all of the
factors mentioned above, including the biological variation that
may result from disease state and lifestyle, need to be established
before such methods can be applied routinely in forensic casework.
4. Conclusions
Forensic age prediction using DNA methylation-based
approaches is a fast-developing ﬁeld of forensic epigenetics that
has a great potential to provide accurate outcomes. Our study
contributes to a range of already published prediction models, not
only by providing potential age-associated markers but also by
introducing a novel methodology in prediction analysis, namely
machine learning by artiﬁcial neural network analysis. The
proposed age prediction model does not only exhibit good
prediction accuracy, but also has the potential to be applied in
individuals of a very wide age range including under-aged children,
individuals of various ethnic backgrounds as well as in non-blood
tissues. Nevertheless, it is believed that prediction can be improved
in the future by normalising for the different technologies of DNA
methylation analysis used. Also, the model worked signiﬁcantly
less accurately in a subset of unhealthy individuals, therefore
testing the markers’ ‘resistance’ to DNA methylation alterations in
disease state should be further tested. To the best of our
knowledge, this is the ﬁrst study that tests the ability of next
generation sequencing technology to detect DNA methylation
variation for age prediction in forensic samples. Following an
extensive validation in future experiments it could provide the
basis to an eventually combined analysis of DNA methylation and
DNA sequence variation in a single streamline using an NGS
platform.
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